Professor Mark Ledwidge, VP Development & Strategy, Solvotrin
Prof. Mark Ledwidge (BSc Pharm, PhD, DBS, MPSI) is Co-Founder and Research Director of the Heartbeat Trust, UCD Professor in the School of Medicine and Medical Science (Adjunct) and Co-Founder/Director of Solvotrin and H&L Pharma.
Following graduation as a pharmacist and completion of a PhD in pharmaceutics at Trinity College, Dublin with Elan Corporation, Mark worked for Baxter Healthcare and Servier Laboratories in technical and marketing roles. He completed a Diploma in Business Strategy before founding the Heartbeat Trust, H&L Pharma and Solvotrin Therapeutics.
His current research interests include: prevention of heart failure; cardiovascular therapeutics and the role of fibrosis in left ventricular dysfunction; iron deficiency in cardiovascular disease; and the role of biomarkers and telemedicine in chronic disease management.
He is inventor on a number of pending and granted patents. Solvotrin successfully launched Active Iron in the UK and Ireland markets in 2016. Mark is Co-Principal Investigator of the St Vincent’s Screening TO Prevent Heart Failure (STOP-HF) programme, which won a Royal College of General Practitioners Award in 2015 and has been incorporated into the 2017 American Heart Association/American College of Cardiology Guidelines.